Processa Pharmaceuticals, Inc. (PCSA) News
Filter PCSA News Items
PCSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PCSA News From Around the Web
Below are the latest news stories about Processa Pharmaceuticals Inc that investors may wish to consider to help them evaluate PCSA as an investment opportunity.
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and |
Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholdersWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate UpdateClinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the quarter ended September 30, 2021, and provides a corporate update. Dr. David |
Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim AnalysisNext Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48 hours after PCS6422 administration, 5-FU potency based on systemic exposure per mg of capecitabine was at least 50 x greater than reported for FDA approved capecitabine.The improved metabolism profile and increased potency did not exist 7 days after PCS6422 administration.The timeline of DPD inhibition and |
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. ESTHANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021. The Company will host a conference call at 5:30 p.m. Eastern Time on Thursday November |
What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares?If you want to know who really controls Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ), then you'll have to look at the... |
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of GastroparesisHANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that they have been cleared by the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, an unmet medical need cond |
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - UpdateHANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date and Time: 9/22/2021 9:05 AM (ET)Webcast: https://wsw.com/webcast/oppenheim |
Processa Pharmaceuticals to Participate in Upcoming Investor ConferencesHANOVER, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date and Time: 9/22/2021 9:05 AM (ET)Webcast: https://wsw.com/webcast/oppenheim |
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the World Orphan Drug Congress USA 2022 Conference, to be held from August 25-27, 2022. Dr. David Young, CEO and Chairman of Processa will deliver a presentation titled “Balancing the Benefit-Risk of an Orph |